Fresh de­lay for $4.3B Roche/Spark deal trig­gers an­a­lyst con­cerns about gene ther­a­py M&A

Roche CEO Sev­erin Schwan may have pre­pared the staff at Spark for the fifth de­lay of its $4.3 bil­lion ac­qui­si­tion — adding a few months …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.